Charles River Laboratories and Wheeler Bio Join Forces to Enhance Biotech Manufacturing Capabilities
WILMINGTON, Mass. & OKLAHOMA CITY Charles River Laboratories International, Inc. a leading contract research organization, has announced a strategic collaboration with Wheeler Bio, Inc. an antibody contract development and manufacturing organization (CDMO). This partnership aims to accelerate the journey from drug discovery to manufacturing by providing biotech companies with access to Wheeler’s Portable CMC (Chemistry, Manufacturing and Controls) platform.
The alliance between Charles River and Wheeler Bio offers early-stage biotechnology companies a unique solution to overcome the challenges they face during preclinical and early clinical supply of recombinant proteins. By leveraging Wheeler’s Portable CMC platform, companies can streamline the development and manufacturing process, effectively reducing timelines and costs associated with bringing new therapies to market.
Furthermore, this collaboration aligns with Charles River’s commitment to innovation and addressing industry needs. The company has long been at the forefront of advancements in biopharmaceutical manufacturing and testing, as demonstrated by their recent introduction of the first rapid animal-free bacterial endotoxin test.
By combining their flagship Endosafe cartridge technology with the recombinant cascade reagent (rCR), Charles River has launched the Endosafe Trillium rCR cartridge offering. This animal-free testing solution expands their robust bacterial endotoxin testing (BET) portfolio, providing biotech companies with a more efficient and ethical alternative for ensuring the safety and quality of their products.
In addition, Charles River further strengthens its support for gene therapy programs with the introduction of off-the-shelf Rep/Cap plasmids. These plasmids are designed to streamline adeno-associated virus (AAV)-based gene therapy manufacturing processes. With the addition of AAV Rep/Cap (RC2, 5, 6, 8, 9) to their comprehensive range of CDMO products, Charles River aims to simplify and accelerate the development of gene therapies, ultimately benefiting patients in need of innovative treatments.
Overall, the collaboration between Charles River and Wheeler Bio represents a significant leap forward in biotech manufacturing capabilities. By providing biotech companies with access to Wheeler’s Portable CMC platform and expanding their testing and manufacturing offerings, Charles River continues to drive innovation and support the advancement of new therapies in the biopharmaceutical industry.
Comments